ストックスクリーナーアプリを入手
57.08
4.08%
-2.425
アフターアワーズ：
56.64
-0.435
-0.76%
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? - The Motley Fool
CRISPR Therapeutics Soars On Gene Therapy Breakout - TipRanks
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 11.2%Time to Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Why CRISPR Therapeutics Is Suddenly Back In Focus - TipRanks
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake - Stock Titan
CRSP|CRISPR Therapeutics AG|Price:53.550|Chg%:-0.440 - TradingKey
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Sahm
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - stocktwits.com
CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise - Sahm
CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares - Stock Titan
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo! Finance Canada
CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP - MarketBeat
Crispr Therapeut (CRSP) Stock News & Updates - Stock Titan
CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value? - Sahm
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock News Today - TradingKey
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings - MarketBeat
California State Teachers Retirement System Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline UpdatesAnd What's Next - webull.com
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking Alpha
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Citi Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocus
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - finance.yahoo.com
CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside - TradingView
CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring the 75% Potential Upside for Investors - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share - GuruFocus
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
CRISPR Therapeutics reports Q2 2026: CASGEVY revenue $76M, net loss $91.2M, cash $2.36B - TradingView
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M - marketscreener.com
CRISPR Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Updates - Quiver Quantitative
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance UK
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value? - Yahoo Finance
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance UK
CRSP|CRISPR Therapeutics AG|Price:46.770|Chg%:+0.230 - TradingKey
BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics - Stock Titan
CRISPR Therapeutics AG (CRSP) Cash Flow - TradingKey
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
CRSP|CRISPR Therapeutics AG|Price:54.407|Chg%:+0.857 - TradingKey
CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990 - TradingKey
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
TradingKey - TradingKey
Affinity Asset Advisors LLC Buys Shares of 150,000 CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
KBC Group NV Acquires 113,997 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary - Quartr
CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary - Quartr
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):